BMO Capital Markets Lowers Omada Health (NASDAQ:OMDA) Price Target to $18.00

Omada Health (NASDAQ:OMDA) had its target price cut by investment analysts at BMO Capital Markets from $27.00 to $18.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 28.39% from the company’s current price.

Several other research firms have also recently weighed in on OMDA. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Omada Health in a research note on Thursday, January 22nd. Barclays dropped their price objective on shares of Omada Health from $22.00 to $17.00 and set an “overweight” rating on the stock in a research note on Tuesday. The Goldman Sachs Group reissued a “buy” rating and set a $26.00 target price on shares of Omada Health in a research note on Friday, January 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Omada Health in a research note on Thursday, January 22nd. Finally, Wells Fargo & Company started coverage on Omada Health in a research report on Thursday, January 8th. They set an “equal weight” rating and a $17.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Omada Health currently has a consensus rating of “Moderate Buy” and an average target price of $23.50.

Omada Health Price Performance

NASDAQ OMDA traded up $0.42 on Friday, hitting $14.02. 3,632,202 shares of the stock were exchanged, compared to its average volume of 1,274,141. The company’s 50-day moving average price is $14.07 and its two-hundred day moving average price is $18.73. Omada Health has a 52-week low of $10.28 and a 52-week high of $28.40. The company has a market capitalization of $811.90 million and a price-to-earnings ratio of -56.08.

Omada Health (NASDAQ:OMDA) last issued its earnings results on Thursday, March 5th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.12. The business had revenue of $75.85 million during the quarter.

Insider Transactions at Omada Health

In other Omada Health news, CEO Sean P. Duffy sold 40,796 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $15.95, for a total value of $650,696.20. Following the completion of the sale, the chief executive officer owned 126,644 shares of the company’s stock, valued at $2,019,971.80. The trade was a 24.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Wei-Li Shao sold 5,618 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $16.13, for a total value of $90,618.34. Following the completion of the transaction, the president directly owned 69,079 shares in the company, valued at $1,114,244.27. The trade was a 7.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 276,893 shares of company stock valued at $4,336,787 in the last ninety days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of OMDA. Strs Ohio acquired a new stake in shares of Omada Health in the third quarter valued at about $38,000. Raymond James Financial Inc. bought a new stake in Omada Health during the 2nd quarter valued at approximately $32,000. Bellevue Group AG grew its holdings in Omada Health by 0.7% in the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock valued at $5,567,000 after buying an additional 1,791 shares during the last quarter. Quarry LP bought a new position in Omada Health in the 4th quarter worth approximately $29,000. Finally, Barclays PLC lifted its holdings in shares of Omada Health by 14.6% during the fourth quarter. Barclays PLC now owns 14,850 shares of the company’s stock worth $234,000 after buying an additional 1,888 shares during the last quarter.

Omada Health News Summary

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 earnings beat and solid top‑line — Omada reported $0.08 EPS vs. consensus (‑$0.04) and $75.85M revenue for Q4, showing strong execution that likely underpins today’s buying. MarketBeat Q4 Results
• Positive Sentiment: Q4/FY highlights show rapid growth and improving profitability — company reported 58% Q4 revenue growth, 53% for the year, 55% member growth, positive net income in Q4 and positive adjusted EBITDA for the year, supporting a re‑rating toward profitability. GlobeNewswire Results
• Positive Sentiment: New product launches expand addressable market — Omada launched GLP‑1 Flex Care for employer customers and new GLP‑1 and cholesterol programs, which could drive member growth and higher revenue per member without employers bearing drug costs directly. GLP‑1 Flex Care Release
• Positive Sentiment: Management set a ~22% revenue growth target for 2026 — the company outlined a double‑digit growth objective while launching new clinical offerings, reinforcing the growth story. Seeking Alpha Growth Target
• Positive Sentiment: Goldman Sachs reiterates Buy — Goldman maintained a Buy rating with a $26 price target, providing analyst support for the outlook. TipRanks / Goldman Sachs
• Neutral Sentiment: FY2026 revenue guidance in line with Street — Omada gave revenue guidance of $312M–$322M (consensus ≈ $312.2M), a range that mostly meets expectations and reduces surprise risk but offers limited upside. Guidance Details
• Neutral Sentiment: Earnings call and transcripts available for deeper color — investors can review the call to validate margin trajectory and member economics. Earnings Transcript (Yahoo)
• Negative Sentiment: Barclays cut its price target to $17 — a notable downward revision that adds near‑term downside pressure relative to higher targets and could temper investor enthusiasm. AmericanBankingNews / Barclays PT
• Neutral Sentiment: Morgan Stanley lowered its PT to $30 but kept an Overweight rating — still represents significant upside vs. current levels, though the cut reduces prior upside expectations. Benzinga / Morgan Stanley

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.